Dementia Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Dementia - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Dementia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Dementia - Overview
  3. Dementia - Therapeutics Development
  4. Dementia - Therapeutics Assessment
  5. Dementia - Companies Involved in Therapeutics Development
  6. Dementia - Drug Profiles
  7. Dementia - Dormant Projects
  8. Dementia - Discontinued Products
  9. Dementia - Product Development Milestones
  10. Appendix

Companies Mentioned

  • Accera Inc
  • Acorda Therapeutics Inc
  • Actinogen Medical Ltd
  • Adamas Pharmaceuticals Inc
  • AgeneBio Inc
  • Anavex Life Sciences Corp
  • Asceneuron SA
  • Axon Neuroscience SE
  • Axovant Sciences Ltd
  • BioArctic AB
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Cortice Biosciences Inc
  • Daewoong Pharmaceutical Co Ltd
  • Echo Pharmaceuticals BV
  • Hyundai Pharmaceutical Co Ltd
  • Ildong Pharmaceutical Co Ltd
  • Immungenetics AG
  • Johnson & Johnson
  • M3 Biotechnology Inc
  • MediPost Co Ltd
  • Neuraltus Pharmaceuticals Inc
  • Neurimmune Holding AG
  • P2D Bioscience
  • Pacific Northwest Biotechnology LLC
  • Pharmasum Therapeutics AS
  • Prana Biotechnology Ltd
  • Sage Therapeutics Inc
  • Sinil Pharmaceutical Co Ltd
  • Stemedica Cell Technologies Inc
  • Theranexus SAS
  • Vicore Pharma AB
  • Voyager Therapeutics Inc
  • WhanIn Pharmaceutical Co Ltd
  • Zhejiang Hisun Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/48j3jn/dementia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs